{
    "clinical_study": {
        "@rank": "62258", 
        "arm_group": [
            {
                "arm_group_label": "treament", 
                "arm_group_type": "Experimental", 
                "description": "herbalife protein shake along with exercise"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "diet and exercise only"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized control trial  of  diet with protein supplementation is being conducted to\n      test the hypothesis that in overweight/obese subjects high protein diet may lead to weight\n      loss and improvement in cardio-metabolic profile."
        }, 
        "brief_title": "Protein Supplementation and Weight Loss", 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Weight Loss"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects aged between 21 -65 years\n\n          2. Subjects with BMI > 23 Kg/m2\n\n        Exclusion Criteria:\n\n          -  Inclusion Criteria:\n\n               1. Subjects aged between 21 -65 years\n\n               2. Subjects with BMI > 23 Kg/m2\n\n        Exclusion Criteria:\n\n          1. Diabetes (type 1 and type 2)\n\n          2. Known or documented coronary heart disease (CHD) (including ECG consistent with prior\n             myocardial infraction), cerebrovascular accident (including transient ischemic\n             attack), peripheral vascular disease (including symptoms of claudication)\n\n          3. Angina or other chest pain that may indicate CHD by history\n\n          4. Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic,\n             endocrine (untreated or unstable), or psychiatric (untreated or unstable) by history\n\n          5. Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use\n             ok), clopidogrel (or equivalent), Coumadin, other investigational drugs within 30\n             days of study entry\n\n          6. Pregnancy or planning pregnancy during the study period by history\n\n          7. Uncontrolled hypertension\n\n          8. Uncontrolled hypothyroidism\n\n          9. Sensitivity or allergy to product by history\n\n         10. Subjects who had undergone bypass procedure\n\n         11. Any debilitating disease such as tuberculosis, HIV by history .\n\n         12. Unwillingness to give written informed consent for participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144636", 
            "org_study_id": "herbalife.2014"
        }, 
        "intervention": {
            "arm_group_label": "treament", 
            "intervention_name": "herbalife protein shake", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Anoop Misra, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Delhi", 
                    "country": "India"
                }, 
                "name": "Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Protein Supplementation on Weight Loss and Cardio Metabolic Profile of Overweight/Obese Subjects", 
        "overall_contact": {
            "last_name": "Anoop Misra, MD", 
            "phone": "49101222"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "weight loss", 
            "safety_issue": "No", 
            "time_frame": "baseline to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144636"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Diabetes Foundation, India", 
            "investigator_full_name": "Dr Anoop Misra", 
            "investigator_title": "Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "improvement in lipid profile", 
            "safety_issue": "No", 
            "time_frame": "baseline - 3 months"
        }, 
        "source": "Diabetes Foundation, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Diabetes Foundation, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}